Recce Ltd has released a press release.
Further Positive Data on RECCE 327 Against MRSA Superbug
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Positive Data on RECCE 327 Against Influenza A
- Recce Signs Phase I Human Clinical Trial Agreement
- First-in-Human Clinical Trial Progress Update
- Half Yearly Report and Accounts
- Positive Efficacy Data in Kidney/UTI infections animal model
Later from Recce Pharmaceuticals
- Positive Data on RECCE 327 Against Neisseria gonorrhoeae
- Response to ASX Price and Volume Query
- RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program
- US Researchers to Test RECCE in Expanded SARS-CoV-2 Program
- Positive Oral Data on New RECCE 435 Against H. pylori
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals